BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 27468884)

  • 1. Regulatory T cells are an important prognostic factor in breast cancer: a systematic review and meta-analysis.
    Wang Y; Sun J; Zheng R; Shao Q; Gao W; Song B; Chen X; Qu X
    Neoplasma; 2016; 63(5):789-98. PubMed ID: 27468884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
    Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
    Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High tumor-infiltrating FoxP3
    Qian F; Qingping Y; Linquan W; Xiaojin H; Rongshou W; Shanshan R; Wenjun L; Yong H; Enliang L
    Eur J Surg Oncol; 2017 Jul; 43(7):1258-1264. PubMed ID: 28214052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory T lymphocyte infiltration in metastatic breast cancer-an independent prognostic factor that changes with tumor progression.
    Stenström J; Hedenfalk I; Hagerling C
    Breast Cancer Res; 2021 Feb; 23(1):27. PubMed ID: 33602289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor secretion of CCL22 activates intratumoral Treg infiltration and is independent prognostic predictor of breast cancer.
    Li YQ; Liu FF; Zhang XM; Guo XJ; Ren MJ; Fu L
    PLoS One; 2013; 8(10):e76379. PubMed ID: 24124553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD8⁺ cytotoxic T cell and FOXP3⁺ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes.
    Liu F; Lang R; Zhao J; Zhang X; Pringle GA; Fan Y; Yin D; Gu F; Yao Z; Fu L
    Breast Cancer Res Treat; 2011 Nov; 130(2):645-55. PubMed ID: 21717105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
    Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
    Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers.
    Tsang JY; Hui SW; Ni YB; Chan SK; Yamaguchi R; Kwong A; Law BK; Tse GM
    Breast Cancer Res Treat; 2014 Jan; 143(1):1-9. PubMed ID: 24272079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and clinical significance of syndecan-1 expression in breast cancer: A systematic review and meta-analysis.
    Qiao W; Liu H; Guo W; Li P; Deng M
    Eur J Surg Oncol; 2019 Jul; 45(7):1132-1137. PubMed ID: 30598194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated expression of FREM1 in breast cancer indicates favorable prognosis and high-level immune infiltration status.
    Li HN; Li XR; Lv ZT; Cai MM; Wang G; Yang ZF
    Cancer Med; 2020 Dec; 9(24):9554-9570. PubMed ID: 33058542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy.
    Montagna E; Vingiani A; Maisonneuve P; Cancello G; Contaldo F; Pruneri G; Colleoni M
    Breast; 2017 Aug; 34():83-88. PubMed ID: 28544923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer.
    Bense RD; Sotiriou C; Piccart-Gebhart MJ; Haanen JBAG; van Vugt MATM; de Vries EGE; Schröder CP; Fehrmann RSN
    J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27737921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor.
    Chen WC; Lai YH; Chen HY; Guo HR; Su IJ; Chen HH
    Histopathology; 2013 Aug; 63(2):225-33. PubMed ID: 23738752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.
    Kwa M; Li X; Novik Y; Oratz R; Jhaveri K; Wu J; Gu P; Meyers M; Muggia F; Speyer J; Iwano A; Bonakdar M; Kozhaya L; Tavukcuoglu E; Budan B; Raad R; Goldberg JD; Unutmaz D; Adams S
    Breast Cancer Res Treat; 2018 Feb; 168(1):57-67. PubMed ID: 29124456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
    Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
    Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
    Eggemann H; Ignatov T; Burger E; Kantelhardt EJ; Fettke F; Thomssen C; Costa SD; Ignatov A
    Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis.
    Chen X; Yuan Y; Gu Z; Shen K
    Breast Cancer Res Treat; 2012 Aug; 134(3):957-67. PubMed ID: 22370627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Survival of patients with metastatic breast cancer according to pathological types of tumors].
    Sánchez R C; Acevedo C F; Petric G M; Galindo A H; Domínguez C F; León R A; Razmilic V D; Ceballos C; Espinoza F; Navarro O ME; Oddó B D; Camus A M
    Rev Med Chil; 2014 Apr; 142(4):428-35. PubMed ID: 25117032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.